NR 566 Week 1 Quiz (With Post-test/Rationale)

1. Question: In addition to methimazole, a symptomatic patient with hyperthyroidism may need a prescription for which of the following medications? 2. Question: Which of the following is a rapid-acting insulin? 3. Question: When methimazole is started for hyperthyroidism how long may it take to see a total reversal of hyperthyroid symptoms? 4. Question: The clinician is providing medication instruction to a patient who was just prescribed ibandronate (Boniva). The patient takes many over the counter vitamin supplements. The clinician knows that many supplements can decrease the absorption of the medication and should not be taken at the same time. The patient should be instructed to take the ibandronate (Boniva) at least 60 minutes before ingestion of which of the following supplements? 5. Question: Which of the following is a potential adverse effect associated with somatropin (Genotropin) use? 6. Question: Which of the following has a duration of action of up to 42 hours, making it an ultra-long acting insulin? 7. Question: A 68-year-old female has been just diagnosed with osteoporosis and has been prescribed alendronate (Fosamax). Which of the following should the clinician include in the patient's education? 8. Question: A 28-year-old female patient (BMI 28) presents to the clinic for her annual physical with no complaints. Which of the following subjective findings from the history should prompt the clinician to screen for diabetes? 9. Question: The onset, peak and duration of isophane insulin (NPH) is which of the following? 10. Question: Secondary hypothyroidism is most commonly due to which of the following? Post-test/Rationale: 1. Question: Which of the following is a rapid-acting insulin product? 2. Question: Basal insulin is responsible for which of the following actions? 3. Question: Which of the following is TRUE when initiating a basal-bolus insulin regimen in patientswith type 2 diabetes mellitus (T2DM)? 4. Question: JP has type 2 diabetes mellitus (T2DM). Her provider has suggested that she initiateinsulin therapy and she brings a prescription for a long-acting basal insulin to yourpharmacy. She is reluctant to use insulin because she thinks insulin is only for patients whoare nearing the end stages of the disease. How can you assure JP this is not the case? 5. Question: Which one of the following is not an open-ended question that may be used to assess apatient’s comfort level with insulin therapy? 6. Question: When educating a patient with type 2 diabetes about administering insulin, all of thefollowing are appropriate recommendations, EXCEPT: 7. Question: RK has diabetes and is using insulin. He loses consciousness from a hypoglycemic event.Which of the following is a possible treatment option for RK? 8. Question: Which of the following is a common adverse event and a patient-level barrier associatedwith insulin use? 9. Question: Consider the onset of action of insulin glulisine (Apidra). When is the most appropriatetime to administer this insulin? 10. Question: A patient is using a basal insulin product and asks if he needs to eat something eachtime he injects it. A correct counseling tip conveyed by the pharmacist might be: